Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Increases By 383.3%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,900 shares, an increase of 383.3% from the May 31st total of 600 shares. Based on an average daily trading volume, of 3,900 shares, the short-interest ratio is currently 0.7 days.

Santen Pharmaceutical Price Performance

SNPHY traded down $0.12 on Thursday, hitting $9.88. The company had a trading volume of 40,570 shares, compared to its average volume of 4,632. The stock has a fifty day moving average price of $10.06 and a 200-day moving average price of $9.90. Santen Pharmaceutical has a 12-month low of $8.15 and a 12-month high of $10.85.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.